We read with interest the article by Ng et al. [1] on the use of curcumin in irritable bowel syndrome (IBS). This work systematically reviewed five randomised-controlled trials, and included three for meta-analysis (a total of 326 subjects). The authors concluded that while safe, well tolerated, and beneficial in reducing IBS symptoms, these results were not statistically significant based on the limited evidence available.
The results of this work indicated improved quality of life and reduced symptoms following treatment. Although this study was a real-life study and included 211 subjects, it did not include a randomised placebo-controlled arm.
In conclusion, while curcumin appears to have potential clinical benefits, especially in the setting of IBS, the definitive role of this intervention is not confirmed. As highlighted by the authors of the meta-analysis, further studies are required. These should be based upon a clear consensus for a consistent therapeutic dose and dosing regimen, whether that be via optimisation of the daily dose or by using an adjuvant to increase bioavailability of curcumin.
